NWPHF (Newron Pharmaceuticals SpA) Total Receivables: $3.75 Mil (As of Dec. 2025)


NWPHF Newron Pharmaceuticals SpA NWPHF
61 GF Score
Price $20.00
GF Value $21.26
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Total Receivables?

Newron Pharmaceuticals SpA NWPHF 61 Total Receivables is $3.75 Mil as of Dec. 2025. GuruFocus rates NWPHF with a GF Score™ of 61/100 and a GF Value™ of $21.26. The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's Total Receivables for the quarter that ended in Dec. 2025 was $3.75 Mil.

Newron Pharmaceuticals SpA Total Receivables Related Terms

Newron Pharmaceuticals SpA Total Receivables Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Total Receivables Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.85 2.55 2.76 44.42 3.75

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.70 44.42 10.65 3.75
NWPHF
61GF Score
Newron Pharmaceuticals SpA NWPHF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $3.75 Mil mean?
Newron Pharmaceuticals SpA (NWPHF) has a Total Receivables of $3.75 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Total Receivables too high?
Newron Pharmaceuticals SpA's current Total Receivables is $3.75 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Total Receivables compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Total Receivables of $3.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Total Receivables is $3.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Newron Pharmaceuticals SpA (NWPHF) has a current Total Receivables of $3.75 Mil. The stock's GF Value™ is $21.26, compared to a current price of $20.00 — trading 5.9% below its estimated fair value. The current Total Receivables is $3.75 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (NWPHF), the current Total Receivables is $3.75 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (NWPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of $20.00 is trading 5.9% below its estimated GF Value™ of $21.26.

Key valuation signals for NWPHF:

  • Total Receivables: $3.75 Mil
  • GF Value™: $21.26 vs. price of $20.00 (5.9% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NWPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
61GF Score

Get the complete analysis for NWPHF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.00
Price
$21.26
GF Value